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Abstract The novel concept of non-ablative fractional
photothermolysis was introduced to the market in 2003 as an
answer to the need for effective, yet low risk, resurfacing
techniques. Unlike conventional ablative and non-ablative
lasers, fractional ablative and non-ablative photothermolysis
treats only a fraction of the skin, leaving up to a maximum of
95% of the skin uninvolved. The undamaged surrounding
tissue allows for a reservoir of viable tissue, permitting
rapid epidermal repair. Non-ablative fractional photother-
molysis is currently approved by the US Food and Drug
Administration (FDA) for the treatment of pigmented
lesions, periorbital rhytides, skin resurfacing, melasma
and soft tissue coagulation, acne and surgical scars, and
actinic keratoses. However, its off-label use is clearly
more extended. In 2007 the concept was further devel-
oped, and ablative fractional photothermolysis was intro-
duced, using an erbium yttrium aluminium garnet (Er:
YAG) or carbon dioxide laser. These devices are FDA
cleared to treat wrinkles, rhytides, furrows, fine lines,
textural irregularities, pigmented lesions and vascular dys-
chromia. In this review we discuss the two concepts, their
technical details and clinical indications, and we describe the
current literature available.
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The novel concept of fractional photothermolysis (FP) was
first reported in 2003, in its basic application [1]. In 2004 and
2005 the first full reports and applications for photoaging by
Manstein et al. followed [2, 3]. This technology has been
developed as a logical next step, triggered by the undesirably
risky, though very effective, ablative technologies and the
limited efficacy of the non-ablative laser modalities. In
contrary to the conventional laser technologies, which target
an entire area of the skin, FP treats only fractions of the skin,
by inducing small three-dimensional zones of thermal
damage, referred to as “Microscopic Thermal Zones”
(MTZs). The surrounding tissue is not involved, which
allows fast epidermal repair via migration of the surrounding
viable cells, hence the name fractional. Depending on the
chosen parameters of energy per MTZ and the density of
MTZs per square centimeter, anywhere from 3–40% of the
skin can be covered with each treatment. The MTZs are
usually smaller than 400 µm in diameter and can penetrate
the skin to varying depths of up to 1,300 µm, depending on
the wavelength, pulse energy, and device chosen. As the
energy of each spot increases, the size/diameter of the MTZ
increases, as well as the depth of penetration. Thus, energy is
chosen based on the desired depth of treatment. Densities
can be reported as either percent coverage, or MTZs per
square centimeter. The terminologies may be congruent at
low energies, but, as the energy increases and the MTZ
increases, these parameters may differ significantly. In order
to translate one devices density settings into another, a
consistent density parameter chosen. Percent coverage is
more translatable, as all MTZ sizes, and individual spots,
differ, not only between devices but also within a single
device. The target chromophore, for all of the fractional
devices on the market at this time, is water. This allows
selective thermal damage to various water-containing struc-
tures, such as collagen, blood-vessels and epidermal kerati-
nocytes [3]. Thermal damage is thus induced in the
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epidermis and dermis, leading to epidermal turnover and
collagen induction. Fractional technologies can be divided
into two main categories, based on the wavelength’s affinity
for water. Those devices with wavelengths that are highly
absorbed by water are termed ablative. These include both
erbium yttrium aluminium garnet (Er:YAG; 2,940 nm) or
yttrium ycandium gallium garnet (YSGG; 2,790 nm) and
carbon dioxide (CO2; 10,600 nm) lasers. Those with
wavelengths only moderately absorbed are ‘non-ablative’
(1,410 nm, 1,440 nm, 1,540 nm, 1,550 nm). Histologically,
with the non-ablative variety, one can observe a column-like
denaturation of the epidermis and dermis, a disruption of the
dermo-epidermal junction, with subepidermal clefting within
the MTZ, and an intact stratum corneum. The surrounding
tissue is unharmed. The thermally destroyed tissue becomes
replaced by keratinocytes that migrate from the surrounding
healthy tissue within the first 24 hours [4]. The button-shaped
necrotic tissue, which is called Microscopic Epidermal
Necrotic Debris (MEND), is eliminated transepidermally by
the keratinocytes, and its migration upwards and through the
stratum corneum is facilitated by the subepidermal clefting.
This migration is called the MEND-shuttle, literally ‘shuttling’
dermal contents out of the skin.Within each amount ofMEND,
elastic tissue, melanin and other dermal contents are found. The
clinical outcome of this process is slight scaling and bronzing of
the skin, which occurs roughly after 1 week. The replacement
of the MTZs with new collagen occurs within 3–6 months.
The results of the ablative fractional technologies have also
been examined. With the ablative approach, histologically one
can see ablated micro-columns, varying in thickness and depth
depending on pulse width and wavelength used. A thin layer
of eschar lines the cavity, which is consistent with ablative
laser treatment. Around these cavities annular coagulation
zones of varying thickness, which represent denatured
collagen, can be observed. Owing to the ablative character of
the procedure, the stratum corneum is mostly absent, contrary
to the situation in non-ablative fractionated technology (Fig. 1)
[5]. Reepithelialization of the coagulation zones occurs
rapidly, within 48 hours [5, 6].
The first medical laser utilizing fractional photothermolysis
technology and consequently the most studied one is the
1,550 nm non-ablative fractional device (Fraxel™ re:store,
Reliant Technologies, San Diego, CA, USA). This device uses
an erbium-doped fiber laser to produce laser light at a
non-ablative wavelength of 1,550 nm. It is not selective for
the other chromophores in the skin, such as melanin or
hemoglobin [7]. The handpiece is handled in a scanning
mode and utilizes an intelligent optical tracking system
(IOTS), which monitors the treatment area and allows the
system to track handpiece velocity, ensuring a unvarying
number and pattern of MTZs. Histological studies using this
device show that full epidermal healing occurs within the
first 24 hours after the procedure [4]. This rapid barrier
restoration lowers the risk of infection, prolonged erythema
and other complications frequently associated with previous
types of resurfacing procedures. This has been supported by
a study showing unchanged transepidermal water loss
(TEWL) within the MTZ [2]. Most of the data discussed
below have been obtained from studies with this device.
Currently, various laser technologies by different producers
that are based on the FP technique exist. They differ in
wavelength, pulse energy and damage pattern. For example,
the Lux 1,540 nm laser (Palomar Medical Technologies,
Burlington, MA, USA) and the Affirm 1,440 nm neodymium
yttrium aluminum garnet (Nd:YAG; Cynosure Inc., Westford,
MA, USA) use stamping technology instead of scanning
mode. There are few studies comparing the different fractional
non-ablative devices, making it difficult to state definitively
which system is superior. Their mechanisms of action and
theoretical basis of function are similar in nature (Table 1).
During the treatment patients feel slight pain. To ease the
pain the skin surface is cooled or topical anaesthesia is used
for pain control. Directly after the treatment with non-ablative
devices, one can observe erythema and edema, which usually
lasts for 1–3 days, again depending on the treatment
parameters used. It is followed by a bronzing and slight
scaling of the skin, which reflects the elimination of the
MENDs. As for ablative fractional treatment, in addition to
Fig. 1 a Schematic histology of non-ablative and ablative FP.
Column-like denaturation of the epidermis and dermis, with a
disruption of the dermo-epidermal junction, clefting within the MTZ,
and an intact stratum corneum. The surrounding tissue is unharmed.
b Schematic histology of ablative FP. Ablated micro-columns, lined
by a thin layer of eschar and with annular coagulation zones
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edema and erythema, which last longer, bleeding and/or oozing
can be observed, and downtime can lasts up to 14 days [8].
As for most laser interventions, the ideal candidate is a
personwith Fitzpatrick skin type I–III. Yet, as the wavelengths
of these devices are not absorbed by melanin, non-ablative
fractional systems can be used for most skin types, and, in fact,
non-ablative FP has been shown to be effective and safe in
darker skin types (IV, V, and VI). A recent pilot study even
showed ablative CO2 FP to be safe for Fitzpatrick phototypes
IV and V [9]. However, the possibility of post-inflammatory
pigment alterations in darker skin types should not be
neglected and should thus be accounted for by adjustment
of treatment settings accordingly. Further, unlike traditional
ablative resurfacing, non-ablative fractional photothermolysis
(NAFP) has been shown to be safe to use on locations other
than the face, and no side-effects such as scarring have been
reported so far [10]. For ablative fractional photothermolysis
(AFP) however, first reports of side-effects and complications
when used off-face or in locations with thin skin, such as the
eyelids, have recently been published. Both publications
reported scarring after the use of a CO2 ablative fractional
device [11, 12]. More data are needed for it to be determined
whether AFP, especially CO2 AFP, should be used at all off
the face and in areas of thin skin. For NAFP and AFP the
patient’s medical history prior to FP should include history
of herpes labialis, as FP can trigger reactivation of herpes
simplex infection. Furthermore, one should inquire about
post-inflammatory hyperpigmentation, tendency for hyper-
trophic scarring or keloids and retinoid use (oral or topical).
There are varying recommendations on the use of oral
retinoids, from pausing them 6–12 months prior to FP to not
stopping them at all [13].
A recent study investigated the short-term side effects after
FP. They showed that 100% of patients had transient
erythema, 82% had edema, 86.6% felt dry skin, 60%
experienced flaking, and 26.6% bronzing [14]. Those more
‘obligatory’ side-effects (pain, erythema, edema) are stronger
and persist longer with higher densities. Increased density
seems to be more likely to produce edema, erythema, and
even post-inflammatory hyperpigmentation than does
increased energy [10]. However, patient satisfaction was
shown to be significantly greater for patients treated with
higher fluences, but not for patients treated with higher
densities [10]. Graber et al. retrospectively evaluated 961
treatments with a 1,550 nm erbium-doped laser for side-
effects and complications [15]. They showed that, overall,
only 7.6% of treatments resulted in complications, the most
frequent of them being acneiform eruptions (1.87%) and
herpes simplex reactivations (1.77%). No difference in side
effects was observed for different skin types and body
locations, except for post-inflammatory hyperpigmentation,
which occurred more frequently in darker skin types. A
simple decrease in treatment density (percentage coverage)
can make this procedure safe for this population.
The ability of both non-ablative and ablative FP to induce
collagen formation has been proven histologically via
demonstration of an increase in collagen type 3 production
after treatment. Collagen production and remodeling clinically
should result in an improvement in rhytides. This, however, is
not always the case [4]. Let us explore the clinical data
Device Company Type Wavelength (nm)
Fraxel re:store™ (former SR 1550) Reliant Erbium fiber 1,550
Fraxel re:fine™ Reliant Erbium fiber 1,410
Fraxel re:pair™ Reliant CO2 10,600
Affirm™ Cynosure Nd:YAG 1,440
Affirm CO2™ Cynosure CO2 10,600
Lux 1540™ Palomar IPL powered laser 1,540
LuxIR Fractional™ Palomar IPL powered infrared 825–1,350
Lux2940™ Palomar Er:YAG 2,940
Active FX™ Lumenis CO2 10,600
Deep FX™ Lumenis CO2 10,600
Pearl™ Cutera YSGG 2,790
Mosaic™ Lutronic CO2 10,600
Er glass 1,550
Juvia CO2 Fractional™ Ellipse CO2 10,600
ProFractional™ Sciton Er:YAG 2,940
Harmony™ Alma Lasers Er:YAG 2,940
Pixel CO2 OMNIFIT™ Alma Lasers CO2 10,600
Mixto SX™ Lasering USA CO2 10,600
Table 1 Ablative and
non-ablative fractional lasers
currently marketed (IPL intense
pulsed light)
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available on non-ablative FP. Manstein et al. treated lateral
peri-orbital rhytides in 30 subjects with four non-ablative FP
treatments over a period of 2–3 weeks [2]. Using the
Fitzpatrick wrinkle score, two independent dermatologists
assessed the treatment effect by blinded analysis of the pre-
treatment photographs and 1-month and 3-month follow-up
photographs. A significant improvement 3 months after
treatment could be demonstrated. Periorbital treatments were
well tolerated.
FP seems to be effective in the treatment of fine and
moderate facial wrinkles, less so, however, for deep lines.
In a recent study 50 patients with cutaneous photodamage,
rhytides, and dyspigmentation were treated three times with
the 1,550 nm non-ablative fractional device at intervals of
3–4 weeks. Clinical improvement was assessed visually,
using comparative photographs at baseline and 3 months,
6 months, and 9 months after treatment. At all time points,
clinical improvement of the face, as well as non-facial skin,
could be shown. In 73% of those treated on the face and 55%
of those treated off face, an improvement in photodamage of
at least 51% to 75% after 9 months was demonstrated [16].
Another study examined the effects of FP on photoaged
hands. Ten patients (skin phototypes II to IV) were
randomized to receive treatment on either the right or left
hand. A total of five treatments to one hand was performed
(1,550 nm Fraxel™, 8–9 mJ per MTZ and density of
2,500 MTZs per square centimeter). Clinical assessment by
patients and physician after 1 month and 3 months showed a
mean improvement of 51% to 75% in skin pigmentation and
25% to 50% in skin wrinkling. An increased density of
dermal collagen was shown histologically both 1 month and
3 months after treatment when compared with that in
baseline biopsies; no statistical analysis was presented on
those findings though [17]. For non-ablative FP the
histologic collagen production does seem to correlate with
a clinical improvement of fine lines.
Non-ablative FP is FDA-approved for the treatment of
pigmented lesions, periorbital rhytides, skin resurfacing,
melasma and soft tissue coagulation, acne and surgical
scars, and actinic keratoses [18]. Though these are the
‘approved’ uses, clearly, there is an even wider array of
clinical indications.
Melasma is a difficult to treat pigmentary disorder with
modest success rates and a high number of recurrences after
most treatment modalities. Fontana Masson staining of
histological sections taken after non-ablative FP have
demonstrated melanin within the MENDs created. This
melanin originates not only from the epidermis, but also
from misplaced dermal melanin, leading to the conclusion
that FP seems to be a convincing therapeutic option for the
treatment of melasma [7]. It has also provided a well-
needed option for the treatment of dermal melasma. In 2005
Tannous and Astner first reported on the treatment of
melasma with the 1,550 nm laser [19]. They treated a
Caucasian female patient (skin type II to III) with epidermal
and dermal melasma twice with full-face fractional
resurfacing three weeks apart. Six months after treatment
they demonstrated a marked reduction in epidermal and
dermal pigment, as assessed by Wood’s lamp examination
and comparative photography.
Rokhsar and Fitzpatrick conducted a pilot study,
treating ten female patients (Fitzpatrick skin types III–V)
suffering from melasma with the 1,550 nm fractional
laser at 1- to 2-week intervals for four to six times [20].
They used 6 mJ to 12 mJ per MTZ and 2,000 to
3,500 MTZs per square centimeter. Three months after
treatment they were evaluated visually, according to the
percentage of lightening of original pigmentation. They
showed 75–100% clearing in 60% of patients, one patient
showed 50–75% of clearance and 30% of patients
achieved less than 25% of clearance. Although rather
darker skin types had been treated (Fitzpatrick skin types
III–V), only one patient showed post-inflammatory
hyperpigmentation. The follow-up period of this study
was too short for recurrence to be assessed. Another study
supported FP as a good treatment option for melasma also
in darker skinned patients [21].
Recently, a study examined the histologic and
ultrastructural changes of melasma after treatment with FP.
Goldberg et al. demonstrated a decrease in melanocytes and a
relative absence of melanin in the surrounding keratinocytes
in post-treatment specimens obtained 3 months after final
treatment in comparison with the pre-treatment ones, assessed
by light and electron microscopy [22]. Investigator assess-
ment showed that the clinical improvement was good for six
subjects with skin type III and fair for four subjects with skin
type IV. It is critical to understand that patients with melasma
are at high risk of hyperpigmentation with any form of
treatment. Fluences and densities used in patients with
melasma should be conservative. Treatments should be
placed further apart than the original publications indicate,
with ideal interval times in the range of 4–6 weeks [17–19].
However, more studies with larger patient populations and
long-term follow-up periods (>6 months) are needed to
finally assess the true value of FP in the treatment of
melasma. At this time, FP should not be used as first line
therapy for the treatment of melasma.
As with the treatment of rhytides, atrophic scars such as
acne scars should also improve after FP therapy, due to new
collagen formation. Moreover, the undesirable side effects
of the very effective original ablative laser resurfacing
fostered the use of FP in the treatment of scars, and, so far,
various studies have examined its effect on different scar
types. For acne scars, ten patients treated with non-ablative
FP for up to three times at 2–3 week intervals all showed
clinical improvement 4 weeks after treatment [23]. In a
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larger study by Alster et al. 53 patients with atrophic scars
were treated with non-ablative FP on a monthly basis for
two or more treatments. Nearly 90% of the patients showed
an improvement of 51–75% after three treatments. Mean
improvement scores increased proportionately with each
successive laser session [24]. A recent study of 27 Korean
patients (Fitzpatrick skin types IV or V) reported a marked
improvement in the appearance of acne scars 3 months after
treatment and proved non-ablative FP to be effective and
safe also for darker skin types [25].
Another pilot study of seven patients and four treatments
at 4-week intervals with the 1,550 nm laser (7–20 mJ, total
density 1,000–2,500 MTZs per square centimeter) demon-
strated improvements of 1–75% in scar hypopigmentation in
six of seven patients [26]. In another case report a white
patient with a surgical scar on the chin was treated with the
1,550 nm Fraxel™ in a single treatment session, using pulse
energy of 8 mJ and density of 2,000 MTZs per square
centimeter. A greater than 75% clinical improvement of the
scar was demonstrated 2 weeks after treatment [27]. Thus,
FP seems to be a valuable treatment modality for atrophic and
potentially hypopigmented scars as well as for surgical scars.
In addition to the above-mentioned clinical indications,
there are various anecdotal reports on the effect of FP on
various other skin disorders, suggesting the potential use of
FP for further indications. Again, controlled studies with
larger patient populations are needed to offer valid
indications and treatment recommendations for FP.
With regard to vascular indications, Glaich et al. reported
on the positive effect of FP on matted telangiectasias on the
thigh of a female patient, skin phototype III, after five
successive treatments at monthly intervals with the
1,550 nm fractional laser [28]. Good results were also
shown for pigmentary disorders other than melasma. Two
male patients with a Becker`s nevus on the chest and on the
cheek, respectively, were treated monthly with the
1,550 nm device with energy densities from 6–10 mJ, final
densities of 2,000–3,048 MTZs per square centimeter, and a
total of five and six treatments, respectively. Both patients
showed a greater than 75% improvement 1 month after
treatment; hypertrichosis remained unaltered [29]. In a
Japanese patient a successful treatment of nevus of Ota
on the face could be achieved with the 1,440 nm Nd:
YAG laser (Affirm) with fluences from 3–5–4.0 J/cm2,
1 cm spot size, single pass with 20% overlap per
treatment. The authors performed two treatments 4 weeks
apart. After the first treatment there was only an
improvement of 10%; however, the nevus of Ota com-
pletely resolved within 6 weeks of the second treatment.
At a 4-month follow-up examination there was still no
recurrence [30].
As striae distensae are, in fact, dermal scars, FP was
hypothesized to be an effective treatment modality. Six
women with striae albae on both buttocks were treated with
1,550 nm FP laser. A substantial improvement in the
appearance of the striae and a partial normalization of skin
elasticity were shown 8 weeks after treatment. Biopsies
revealed a significant increase in epidermal thickness,
collagen, and elastic fiber deposition after FP [31]. One
patient with poikiloderma of Civatte showed complete
resolution of the pigmentary changes after one FP treatment
at 8 mJ/cm2 with 2,000 MTZs per square centimeter [32].
In a recent case report a residual hemangioma was treated
with the 1,440 nm fractional laser. The treatment was
applied to the pretreated and now wrinkled and hypertrophic
skin, using a 15 mm handpiece, energy density of 25 J/cm2
and a density of 10; 8–10 successive passes resulted in a
total energy of 2.4 kJ. After two treatments, the skin showed
marked clinical improvement in surface and texture at
1 month and 6-month follow-ups [33].
Non-ablative FP can also be used in combination
therapy. One case report discusses the potential of future
combination therapy of FP with Botulinum toxin injections
to enhance the results of the laser treatment [34]. In another
pilot study the synergistic effects of combined fractional
resurfacing and 5-aminolevulinic acid–photodynamic therapy
(ALA-PDT) in the treatment of skin rejuvenation were
evaluated [35]. Four women (skin phototypes II or III) with
mild to moderate perioral rhytides were treated with two
sessions of FP (Fraxel SR™), with a 3-week interval, and
immediately after each fractional treatment they were treated
with ALA-PDT on one-half of the peri-oral area. The
combined treatment side showed increased improvement in
superficial wrinkles in 75% of subjects. Thus, combination
treatments of FP with other therapies to enhance the effects
of one or the other or to achieve synergistic effects are to be
investigated in further detail.
Ablative fractional photothermolysis can be achieved using
an Er:YAG, YSGG, or CO2 laser, with high absorption of
these wavelengths by water [5, 36]. Originally, the ablative
FP devices introduced used larger, millimeter, spot sizes.
More recently these devices have been modified to introduce
micron-sized pulses, allowing deeper penetration of the
ablative wavelength. Ablative fractional devices on the market
also differ in maximum power, energy and penetration depth.
There are considerably fewer data published onAFP, andmost
focus on the treatment of photodamaged skin. In a
preliminary clinical report in 2007 the non-sequential
fractional ultra-pulsed 10,600 nm CO2 light treatment
ActiveFX™ laser (Lumenis Inc., Santa Clara, CA, USA)
was evaluated for the treatment of photodamaged facial
skin [37]. Fifty-five subjects showed significant differences
between baseline photographs and those taken 1-month and
3 months after treatment for all aspects of photodamaged skin
(global score, fine lines, mottled pigmentation, sallow
complexion, tactile roughness, coarse wrinkles) except
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telangiectasias. Adverse side effects were minimal, and
downtime very low.
Another recent study reported on this new technology,
using a 2,940 nm Er:YAG laser (Pixel, Alma Lasers,
Buffalo Grove, IL, USA) for fractional resurfacing of
photoaged skin [6]. They treated 30 women, Fitzpatrick
skin types II–IV with one single session of fractional
resurfacing, and 93% of the patients showed a good or very
good improvement of the wrinkles. Except for one case of
hyperpigmentation in a phototype IV patient, no side effects
were observed. Two further studies confirmed that micro-
fractional ablative treatment with 2,790 nm and 2,940 nm
erbium lasers is a safe and effective treatment for wrinkle
reduction and results in only minimal patient downtime
[38–40]. Supporting data have recently been published by
Berlin et al. Ten patients, Fitzpatrick skin types I–III,
with photodamaged facial skin were given a single-pass
superficial full-face ablative treatment using the CO2
laser at energy levels of 80–100 mJ. Clinical improvement
in cutaneous photo-aging was observed. Interestingly,
subjects treated with lower density settings reported a
better mean improvement after 24 weeks than did subjects
treated with higher density settings; however, the result
was not statistically significant (P=0.27). Biopsies
obtained after treatment showed greater fibrosis. Via
electron microscopy, a decreased average diameter of the
collagen fibrils was noted, which the authors concluded to
be consistent with greater deposition of collagen type III
as a feature of new collagen formation [41].
As for the use of ablative FP in the treatment of acne
scars, Chapas et al. treated 13 patients, skin types I–IV,
with the 10,600 CO2 ablative fractional device (Fraxel re:
pair™, Reliant Technologies), using a spot size of
120 µm, pulse energies of 20–100 mJ and densities of
100–400 MTZs per square centimeter per pass and a total
of 200–1,200 MTZs per square centimeter. Two to three
treatments at 1–2 month intervals were administered.
Illustrated by a three-dimensional optical profiling system,
objective improvements on the depths of the acneiform
scars ranged from 43–79.9%, with a mean of 66.8%.
Further, post-treatment side effects were rated as mild to
moderate, and no delayed pigmentary complications were
observed [42]. In a recent study seven patients skin types
IV and V received one single facial treatment with the
ultra-pulsed 10,600 nm CO2 light treatment ActiveFX™
laser (Lumenis Inc.), using a spot diameter of 1.3 mm and
60 mJ. At a density setting of 1, approximately 60% of the
facial skin surface was ablated. During a follow-up of up
to 6 months, treatment-induced hyperpigmentation was
not observed in any subject [9].
A study from Korea compared the treatment of atrophic
facial acne scars in 20 patients with skin phototypes IV–V
[43]. One group was treated with a single pass of an
ablative fractional CO2 laser (CoScan-5000, Stratek, Inc.,
Anyang, South Korea) using high energy settings [0.2 mm
dot size, 30 ms pulse duration, 50–70 mJ pulse energy,
0.8 mm dot pitch (interlesional distance), 400 dots in a
20 mm×20 mm scanned area, 20% of treated area], and the
other group was treated with the same laser using low energy
settings [0.2 mm dot size, 30 ms pulse duration, 15–35 mJ
pulse energy, 0.8 mm dot pitch (interlesional distance), and
400 dots in a 20 mm×20 mm scanned area]. Both groups
received three successive monthly treatments on only one-half
of the face. The other half of the face, in both groups, was
treated with the same ablative fractional laser with low energy
plus, directly before the ablative treatment, a non-ablative
long-pulse 1,064 nmNd:YAG laser. Of the ten patients treated
with high energy settings, two showed 30–49% improvement,
and eight patients had 50–69% improvement, in comparison
with the patients treated with low energy settings, of whom
seven had 10–39% improvement and three had 40– 59%
improvement. Thus, higher energy settings resulted in
improvement in the patients’ acne scars. However, the
combination of ablative fractional laser resurfacing and
non-ablative laser resurfacing yielded the best results, with
fewer complications observed. Some cases of transient
hyperpigmentation were observed, which resolved completely
within 6 weeks after the use of topical bleaching agents. Other
complications, such as hypopigmentation, bleeding, or hyper-
trophic scarring, were not observed throughout the 12-month
study period. There are also case reports on the improvement
of burns scars, both on and off face, after treatment with
ablative fractional resurfacing [44, 45]. Still, the safety of
ablative FP needs to be examined in multiple patients of
different ethnicities before a conclusion on its safety in
darker skin types can be stated. To date, there have been no
reports of depigmentation in ablative FP, as was previously
seen with the traditional CO2 resurfacing lasers.
Currently, there are no studies comparing non-ablative
fractional photothermolysis with ablative fractional photo-
thermolysis. However, as for now, data suggest that the
ablative fractional treatment is safe, with rapid healing times
and minimal downtime, especially for single-pass treatments.
Most patients treated with Er:YAG FT devices will have a
downtime anywhere from 1–3 days; those treated with the
CO2 devices may have 3–7 days downtime. Erythema and
edema are common, and desquamation may follow for
several days afterward. One has to bear in mind though, that
with multiple passes, the ablative damage accumulates,
which increases thermal damage and consequently healing
times [37]. Safety for the darkest skin types (Fitzpatrick V
and VI) has yet to be determined for the fractional ablative
devices. It is possible that another skin typing system more
predictive of identifying those likely to develop abnormal
pigmentation should be used to establish those patients at
most risk of dyspigmentation.
142 Lasers Med Sci (2010) 25:137–144
The ablative fractional regimen offers an interesting
alternative to the conventional approach of multi-session
non-ablative fractional resurfacing. However, studies
comparing the effect of non-ablative FP with that of
ablative FP are needed. As FP is a relatively new
technology, there is a limited number of studies. In
particular, there is a lack of controlled large-scaled trials
with long-term follow-ups. However, the current studies
do provide sufficient data to support the use of FP
technology as a safe and effective treatment modality for
various clinical indications. Preliminary data suggest that
the combination of ablative and non-ablative fractional
photothermolysis might deliver promising results. We look
forward to the future, which will bring consistent treatment
regimens for each method of fractional resurfacing, including
standardization of density settings between devices.
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